Human teratogens and evidence-based teratogen risk counseling: The Motherisk approach

Clinical Obstetrics and Gynecology

Volumn 50, Issue 1, 2007, Pages 123-131

  Nava Ocampo, Alejandro A ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Maternal fetal relations; Maternal health services; Prenatal care; Risk benefit assessment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; COUMARIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID ANTAGONIST; ISOTRETINOIN; LAMOTRIGINE; METHOTREXATE; OMEPRAZOLE; SEROTONIN UPTAKE INHIBITOR; TERATOGENIC AGENT; THALIDOMIDE; VALPROIC ACID; WARFARIN;

ADAPTATION SYNDROME; ARTICLE; ASTHMA; BIRTH DEFECT; CHEMOTHERAPY; CONGENITAL MALFORMATION; COUNSELING; DOSE RESPONSE; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; PRENATAL DRUG EXPOSURE; PROGNOSIS; RISK ASSESSMENT; SAFETY; SIDE EFFECT; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ATTITUDE OF HEALTH PERSONNEL; COUNSELING; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MOTHERS; PREGNANCY; RISK; TERATOGENS;

EID: 33847114324     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31802f1880     Document Type: Article

References (42)

1. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perpect. 1998;30:24-29, 46.
2. Han JY, Nava-Ocampo AA, Koren G. Unintended pregnancies and exposure to potential human teratogens. Birth Defects Res A Clin Mol Teratol. 2005;73:245-248.
3. Dunne F. Type 2 diabetes and pregnancy. Semin Fetal Neonatal Med. 2005;10:333-339.
4. Abel EL. Smoking in pregnancy. J Psychoactive Drugs. 1984;16:327-338.
5. Martin TR, Bracken MD. Association of low birth weight with passive smoke exposure in pregnancy. Am J Epidemiol. 1986;124:633-642.
6. Welch-Carre E. The neurodevelopmental consequences of prenatal alcohol exposure. Adv Neonatal Care. 2005;5:217-229.
7. Sulik KK. Genesis of alcohol-induced craniofacial dysmorphism. Exp Biol Med (Maywood). 2005;230:366-375.
8. Martinez-Frias ML, Bermejo E, Rodriguez-Pinilla E, et al. Risk for congenital anomalies associated with different sporadic and daily doses of alcohol consumption during pregnancy: a case-control study. Birth Defects Res A Clin Mol Teratol. 2004;70:194-200.
9. McNamara TK, Orav EJ, Wilkins-Haug L, et al. Risk during pregnancy-self-report versus medical record. Am J Obstet Gynecol. 2005;193:1981-1985.
10. Anderson GD. Pregnancy-induced changes in pharmacokinetics. A mechanisticbased approach. Clin Pharmacokinet. 2005;44:989-1008.
11. Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indication, mechanisms of action and side effects. Br J Dermatol. 2005;153:254-273.
12. Sze DM, Brown R, Yang S, et al. The use of thalidomide in myeoloma therapy as an effective anticancer drug. Curr Cancer Drug Targets. 2006;6:325-331.
13. Koren G, Bologa M, Long D, et al. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol. 1989;160:1190-1194.
14. Koren G, Bologa M, Pastuzak A. Women's perception of teratogenic risk. Can J Public Health. 1991;82:S11-S14, S33-S37.
15. Koren G, Pastuszak A. Prevention of unnecessary pregnancy terminations by counseling women on drug, chemical, and radiation exposure during pregnancy. Teratology. 1990;41:657-661.
16. Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health. 1995;68:66-70.
17. Ornstein M, Einarson A, Koren G. Bendectin/Dickectin for morning sickness: a Canadian follow-up of an American tragedy. Reprod Toxicol. 1995;9:1-6.
18. Einarson A, Koren G. Counseling pregnant women treated with paroxetine. Concern about cardiac malformations. Can Fam Physician. 2006;52:593-594.
19. Marden PM, Smith DW, McDonald MJ. Congenital anomalies in the newborn infant, including minor variations. J Pediatr. 1964;64:357-371.
20. Schardein JL. Chemically Induced Birth Defects. New York: Marcel Dekker, Inc; 2000.
21. Einarson A, Lockett D. Do we have a knowledge transfer and translation plan at Teratogen Information Services? Reprod Toxicol. 2006;22:542-545.
22. Oduncu FS, Kimmig R, Hepp H, et al. Cancer in pregnancy: maternal-fetal conflict. J Cancer Res Clin Oncol. 2003;129:133-146.
23. Jungmann EM, Mercey D, De Ruiter A, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect. 2001;77:441-443.
24. Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and loss of pregnancy. N Engl J Med. 1999;340:1796-1799.
25. Koren G, Nava-Ocampo AA, Moretti ME, et al. Motherisk update: major malformations with valproic acid. Can Fam Physician. 2006;52:441-447.
26. Lewden B, Vial T, Elefant E, et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol. 2004;31:2360-2365.
27. De Santis M, Lucchese A, Carducci B, et al. Risk of drug-induced congenital defects. Eur J Obstet Gynecol Reprod Biol. 2004;117:10-19.
28. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Pyschiatry. 2006;77:193-198.
29. Felkamp M, Care JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 1993;47:533-539.
30. Nava-Ocampo AA, Velazquez-Armenta EY, Han JY, et al. Use of proton pump inhibitors during pregnancy and breast-feeding. Can Fam Physician. 2006;52:853-854.
31. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature reviews and implications for clinical applications. JAMA. 2005;293:2372-2383.
32. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194:961-966.
33. Einarson A. Abrupt discontinuation of psychotropic drugs following confirmation of pregnancy: a risky practice. J Obstet Gynaecol Can. 2005;27:1019-1022.
34. Ross HL, Elias S. Maternal serum screening for fetal genetic disorders. Obstet Gynecol Clin North Am. 1997;24:33-47.
35. Dashe JS, Twickler DM, Santos-Ramos R, et al. Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound. Am J Obstet Gynecol. 2006. In press.
36. Carvalho JS. Fetal heart scanning in the first trimester. Prenat Diagn. 2004;24:1060-1067.
37. Enriquez R, Wu P, Griffin MT, et al. Cessation of asthma medication in early pregnancy. Am J Obstet Gynecol. 2006;195:149-153.
38. Alexander S, Dodds L, Armson BA. Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol. 1998;92:435-440.
39. Bracken MB, Triche EW, Belanger K, et al. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. Obstet Gynecol. 2003;102:739-752.
40. Olesen C, Thrane N, Nielsen GL, et al. EuroMAP Group. A population-based prescription study of asthma drugs during pregnancy: changing the intensity of asthma therapy and perinatal outcomes. Respiration. 2001;68:256-261.
41. Schatz M, Dombrowski MP, Wise R, et al. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol. 2004;113:1040-1045.
42. NAEPP Expert Panel Report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol. 2005;115:34-46.